

1/17





FIG. 1

2/17



3/17








FIG. 2g



5/17




FIG. 2i

6/17




FIG. 3

7/17




FIG. 4

8/17





FIG. 5

9/17



Retroviral helper cell

FIG. 6



11/17

a. 1 2 3 4 5



-5kb-
-2.4kb-

b. 1 2 3 4 5



c. 1 2 3



-5kb-
-2.4kb-

d. 1 2 3



FIG. 8

12/17




FIG. 9

13/17

TOPDOWN ELECTROPHORESIS




FIG. 10A




FIG. 11A




FIG. 10B



FIG. 10C

| vector | cell line | neo protein | titer |
|--------|-----------|-------------|------------|
| VLPBN | GPE86 | 3.4ng/mg | 1.65 x EE4 |
| VLPBN | GPE86 | 1.57ng/mg | 5.6 x EE4 |
| VLCN | GPE86 | 3.74ng/mg | 2 x EE5 |
| VLDN | GPE86 | 3.87ng/mg | 7.5 x EE4 |
| VLPBN | PA317 | 1.25ng/mg | ND |
| VLPBN | PA317 | 1.92ng/mg | ND |
| VLCN | PA317 | 1.59ng/mg | ND |
| VLDN | PA317 | 1.77ng/mg | ND |

FIG. 11B

14/17





FIG. 12A



EIC 120

15/17




FIG. 12C




FIG. 12D

16/17

1 2 3 4 5 6 7 8 9 10



FIG. 13A

1 2 3 4 5 6 7 8



FIG. 13B

1 2 3 4 5 6 7




FIG. 13C

00001110 0000101

17/17

VL30-MVM HYBRID FOR TUMOR EXPRESSION




FIG. 14